25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Tasly Pharmaceutical Group Co Ltd
Buy, Hold or Sell?

Let's analyze Tasly Pharmaceutical Group Co Ltd together

I guess you are interested in Tasly Pharmaceutical Group Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Tasly Pharmaceutical Group Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Tasly Pharmaceutical Group Co Ltd

I send you an email if I find something interesting about Tasly Pharmaceutical Group Co Ltd.

1. Quick Overview

1.1. Quick analysis of Tasly Pharmaceutical Group Co Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Tasly Pharmaceutical Group Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.05
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥8.60
Expected worth in 1 year
¥8.84
How sure are you?
92.5%

+ What do you gain per year?

Total Gains per Share
¥0.61
Return On Investment
4.1%

For what price can you sell your share?

Current Price per Share
¥14.90
Expected price per share
¥14.64 - ¥17.65
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Tasly Pharmaceutical Group Co Ltd (5 min.)




Live pricePrice per Share (EOD)
¥14.90
Intrinsic Value Per Share
¥7.75 - ¥23.69
Total Value Per Share
¥16.35 - ¥32.29

2.2. Growth of Tasly Pharmaceutical Group Co Ltd (5 min.)




Is Tasly Pharmaceutical Group Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$1.8b$1.7b$25.2m1.4%

How much money is Tasly Pharmaceutical Group Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$36m$30.1m$5.8m16.4%
Net Profit Margin11.7%9.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Tasly Pharmaceutical Group Co Ltd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Tasly Pharmaceutical Group Co Ltd?

Welcome investor! Tasly Pharmaceutical Group Co Ltd's management wants to use your money to grow the business. In return you get a share of Tasly Pharmaceutical Group Co Ltd.

First you should know what it really means to hold a share of Tasly Pharmaceutical Group Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Tasly Pharmaceutical Group Co Ltd is ¥14.90. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Tasly Pharmaceutical Group Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Tasly Pharmaceutical Group Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥8.60. Based on the TTM, the Book Value Change Per Share is ¥0.06 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.09 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Tasly Pharmaceutical Group Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.030.2%0.020.2%0.020.2%0.020.2%0.030.2%
Usd Book Value Change Per Share-0.01-0.1%0.010.1%0.000.0%0.010.0%0.020.1%
Usd Dividend Per Share0.050.3%0.010.1%0.010.1%0.020.1%0.030.2%
Usd Total Gains Per Share0.030.2%0.020.1%0.020.1%0.020.1%0.050.3%
Usd Price Per Share1.77-2.11-1.76-2.01-3.52-
Price to Earnings Ratio12.80-53.76-24.66-30.81-36.47-
Price-to-Total Gains Ratio50.85--478.32-100.92--117.07--16.88-
Price to Book Ratio1.46-1.76-1.49-1.72-4.31-
Price-to-Total Gains Ratio50.85--478.32-100.92--117.07--16.88-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.09196
Number of shares478
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.02
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.020.02
Gains per Quarter (478 shares)10.3010.56
Gains per Year (478 shares)41.1942.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1251631291332
2503372582674
374491138739116
4996615411752158
51248219514665200
61499823617579242
717411527720492284
8198131318233105326
9223147359262118368
10248164400292131410

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%38.02.00.095.0%86.02.00.097.7%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%13.07.00.065.0%28.012.00.070.0%65.023.00.073.9%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%84.00.04.095.5%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%17.03.00.085.0%37.03.00.092.5%80.08.00.090.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Tasly Pharmaceutical Group Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0900.061-247%0.033-376%0.049-285%0.141-164%
Book Value Per Share--8.5978.557+0%8.421+2%8.342+3%7.006+23%
Current Ratio--2.9543.288-10%3.837-23%3.518-16%2.009+47%
Debt To Asset Ratio--0.2700.263+3%0.253+7%0.290-7%0.414-35%
Debt To Equity Ratio--0.3800.366+4%0.348+9%0.471-19%0.852-55%
Dividend Per Share--0.3370.092+265%0.092+267%0.109+211%0.202+67%
Eps--0.2460.172+43%0.174+41%0.174+41%0.205+20%
Free Cash Flow Per Share--0.7560.342+121%0.327+131%0.280+169%0.188+301%
Free Cash Flow To Equity Per Share--0.7560.342+121%0.326+132%0.068+1009%0.080+846%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--23.690--------
Intrinsic Value_10Y_min--7.751--------
Intrinsic Value_1Y_max--1.364--------
Intrinsic Value_1Y_min--0.762--------
Intrinsic Value_3Y_max--4.868--------
Intrinsic Value_3Y_min--2.317--------
Intrinsic Value_5Y_max--9.299--------
Intrinsic Value_5Y_min--3.887--------
Market Cap22259854284.800+16%18793891062.90022540491935.913-17%18776245627.600+0%21574934120.030-13%37696478205.802-50%
Net Profit Margin--0.1580.117+35%0.096+64%0.107+48%0.101+57%
Operating Margin----0%0.138-100%0.096-100%0.065-100%
Operating Ratio--1.0951.149-5%1.170-6%1.273-14%1.056+4%
Pb Ratio1.733+16%1.4631.760-17%1.486-2%1.719-15%4.311-66%
Pe Ratio15.159+16%12.79953.762-76%24.660-48%30.805-58%36.468-65%
Price Per Share14.900+16%12.58015.058-16%12.520+0%14.313-12%25.099-50%
Price To Free Cash Flow Ratio4.930+16%4.1628.400-50%-12.126+391%32.497-87%5.520-25%
Price To Total Gains Ratio60.230+16%50.852-478.323+1041%100.920-50%-117.069+330%-16.880+133%
Quick Ratio--0.6670.475+40%1.876-64%1.698-61%1.351-51%
Return On Assets--0.0210.015+43%0.012+67%0.014+44%0.017+21%
Return On Equity--0.0290.020+43%0.017+68%0.021+42%0.033-11%
Total Gains Per Share--0.2470.153+61%0.125+99%0.157+57%0.342-28%
Usd Book Value--1803155595.4501798243201.325+0%1773028385.022+2%1764661975.741+2%1481856462.209+22%
Usd Book Value Change Per Share---0.0130.009-247%0.005-376%0.007-285%0.020-164%
Usd Book Value Per Share--1.2071.201+0%1.182+2%1.171+3%0.984+23%
Usd Dividend Per Share--0.0470.013+265%0.013+267%0.015+211%0.028+67%
Usd Eps--0.0340.024+43%0.024+41%0.024+41%0.029+20%
Usd Free Cash Flow--158484819.63271930446.790+120%68775807.213+130%59278066.676+167%34926706.255+354%
Usd Free Cash Flow Per Share--0.1060.048+121%0.046+131%0.039+169%0.026+301%
Usd Free Cash Flow To Equity Per Share--0.1060.048+121%0.046+132%0.010+1009%0.011+846%
Usd Market Cap3125283541.586+16%2638662305.2313164685067.802-17%2636184886.115+0%3029120750.452-13%5292585540.095-50%
Usd Price Per Share2.092+16%1.7662.114-16%1.758+0%2.010-12%3.524-50%
Usd Profit--51540454.82436022317.480+43%30128050.382+71%35553100.385+45%42693908.159+21%
Usd Revenue--326161061.316303746725.033+7%314999401.646+4%370293681.687-12%456048203.841-28%
Usd Total Gains Per Share--0.0350.022+61%0.017+99%0.022+57%0.048-28%
 EOD+4 -4MRQTTM+26 -8YOY+25 -105Y+26 -910Y+23 -12

3.3 Fundamental Score

Let's check the fundamental score of Tasly Pharmaceutical Group Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.159
Price to Book Ratio (EOD)Between0-11.733
Net Profit Margin (MRQ)Greater than00.158
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.667
Current Ratio (MRQ)Greater than12.954
Debt to Asset Ratio (MRQ)Less than10.270
Debt to Equity Ratio (MRQ)Less than10.380
Return on Equity (MRQ)Greater than0.150.029
Return on Assets (MRQ)Greater than0.050.021
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Tasly Pharmaceutical Group Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.571
Ma 20Greater thanMa 5015.298
Ma 50Greater thanMa 10014.526
Ma 100Greater thanMa 20013.898
OpenGreater thanClose14.890
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Tasly Pharmaceutical Group Co Ltd

Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. It provides cardiovascular, anti-tumor, cold and fever, liver disease treatment, and other disease solutions. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is based in Tianjin, China.

Fundamental data was last updated by Penke on 2024-10-30 11:32:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Tasly Pharmaceutical Group Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Tasly Pharmaceutical Group Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 15.8% means that ¥0.16 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 15.8%. The company is making a huge profit. +2
  • The TTM is 11.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ15.8%TTM11.7%+4.1%
TTM11.7%YOY9.6%+2.1%
TTM11.7%5Y10.7%+1.1%
5Y10.7%10Y10.1%+0.6%
4.3.1.2. Return on Assets

Shows how efficient Tasly Pharmaceutical Group Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Tasly Pharmaceutical Group Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.1% Return on Assets means that Tasly Pharmaceutical Group Co Ltd generated ¥0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 2.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.1%TTM1.5%+0.6%
TTM1.5%YOY1.2%+0.2%
TTM1.5%5Y1.4%+0.0%
5Y1.4%10Y1.7%-0.3%
4.3.1.3. Return on Equity

Shows how efficient Tasly Pharmaceutical Group Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Tasly Pharmaceutical Group Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.9% Return on Equity means Tasly Pharmaceutical Group Co Ltd generated ¥0.03 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 2.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.9%TTM2.0%+0.9%
TTM2.0%YOY1.7%+0.3%
TTM2.0%5Y2.1%0.0%
5Y2.1%10Y3.3%-1.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Tasly Pharmaceutical Group Co Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Tasly Pharmaceutical Group Co Ltd is operating .

  • Measures how much profit Tasly Pharmaceutical Group Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Tasly Pharmaceutical Group Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY13.8%-13.8%
TTM-5Y9.6%-9.6%
5Y9.6%10Y6.5%+3.1%
4.3.2.2. Operating Ratio

Measures how efficient Tasly Pharmaceutical Group Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.10 means that the operating costs are ¥1.10 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 1.095. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.149. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.095TTM1.149-0.054
TTM1.149YOY1.170-0.020
TTM1.1495Y1.273-0.124
5Y1.27310Y1.056+0.217
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Tasly Pharmaceutical Group Co Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Tasly Pharmaceutical Group Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.95 means the company has ¥2.95 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 2.954. The company is able to pay all its short-term debts. +1
  • The TTM is 3.288. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.954TTM3.288-0.335
TTM3.288YOY3.837-0.549
TTM3.2885Y3.518-0.229
5Y3.51810Y2.009+1.509
4.4.3.2. Quick Ratio

Measures if Tasly Pharmaceutical Group Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Tasly Pharmaceutical Group Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.67 means the company can pay off ¥0.67 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 0.667. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.475. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.667TTM0.475+0.192
TTM0.475YOY1.876-1.401
TTM0.4755Y1.698-1.223
5Y1.69810Y1.351+0.348
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Tasly Pharmaceutical Group Co Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Tasly Pharmaceutical Group Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Tasly Pharmaceutical Group Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.27 means that Tasly Pharmaceutical Group Co Ltd assets are financed with 27.0% credit (debt) and the remaining percentage (100% - 27.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 0.270. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.263. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.270TTM0.263+0.008
TTM0.263YOY0.253+0.010
TTM0.2635Y0.290-0.028
5Y0.29010Y0.414-0.124
4.5.4.2. Debt to Equity Ratio

Measures if Tasly Pharmaceutical Group Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Tasly Pharmaceutical Group Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 38.0% means that company has ¥0.38 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tasly Pharmaceutical Group Co Ltd:

  • The MRQ is 0.380. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.366. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.380TTM0.366+0.014
TTM0.366YOY0.348+0.018
TTM0.3665Y0.471-0.106
5Y0.47110Y0.852-0.381
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Tasly Pharmaceutical Group Co Ltd generates.

  • Above 15 is considered overpriced but always compare Tasly Pharmaceutical Group Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 12.80 means the investor is paying ¥12.80 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tasly Pharmaceutical Group Co Ltd:

  • The EOD is 15.159. Based on the earnings, the company is fair priced.
  • The MRQ is 12.799. Based on the earnings, the company is underpriced. +1
  • The TTM is 53.762. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD15.159MRQ12.799+2.360
MRQ12.799TTM53.762-40.963
TTM53.762YOY24.660+29.102
TTM53.7625Y30.805+22.957
5Y30.80510Y36.468-5.663
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Tasly Pharmaceutical Group Co Ltd:

  • The EOD is 4.930. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 4.162. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 8.400. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.930MRQ4.162+0.768
MRQ4.162TTM8.400-4.238
TTM8.400YOY-12.126+20.526
TTM8.4005Y32.497-24.097
5Y32.49710Y5.520+26.977
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Tasly Pharmaceutical Group Co Ltd is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Tasly Pharmaceutical Group Co Ltd:

  • The EOD is 1.733. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.463. Based on the equity, the company is underpriced. +1
  • The TTM is 1.760. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.733MRQ1.463+0.270
MRQ1.463TTM1.760-0.297
TTM1.760YOY1.486+0.275
TTM1.7605Y1.719+0.041
5Y1.71910Y4.311-2.592
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets17,604,264
Total Liabilities4,761,275
Total Stockholder Equity12,531,089
 As reported
Total Liabilities 4,761,275
Total Stockholder Equity+ 12,531,089
Total Assets = 17,604,264

Assets

Total Assets17,604,264
Total Current Assets9,758,274
Long-term Assets7,845,990
Total Current Assets
Cash And Cash Equivalents 4,459,568
Short-term Investments 1,336,173
Net Receivables 868,391
Inventory 1,815,560
Other Current Assets 19,250
Total Current Assets  (as reported)9,758,274
Total Current Assets  (calculated)8,498,942
+/- 1,259,332
Long-term Assets
Property Plant Equipment 3,672,196
Goodwill 15,880
Intangible Assets 2,100,913
Long-term Assets Other 49,902
Long-term Assets  (as reported)7,845,990
Long-term Assets  (calculated)5,838,890
+/- 2,007,100

Liabilities & Shareholders' Equity

Total Current Liabilities3,303,741
Long-term Liabilities1,457,534
Total Stockholder Equity12,531,089
Total Current Liabilities
Short Long Term Debt 823,420
Accounts payable 1,590,932
Other Current Liabilities 70,043
Total Current Liabilities  (as reported)3,303,741
Total Current Liabilities  (calculated)2,484,395
+/- 819,346
Long-term Liabilities
Long term Debt 1,237,827
Capital Lease Obligations Min Short Term Debt64,634
Long-term Liabilities  (as reported)1,457,534
Long-term Liabilities  (calculated)1,302,461
+/- 155,073
Total Stockholder Equity
Retained Earnings 8,461,056
Total Stockholder Equity (as reported)12,531,089
Total Stockholder Equity (calculated)8,461,056
+/- 4,070,033
Other
Capital Stock1,493,950
Common Stock Shares Outstanding 1,493,950
Net Invested Capital 14,592,336
Net Working Capital 6,454,533
Property Plant and Equipment Gross 7,528,527



6.2. Balance Sheets Structured

Currency in CNY. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302001-12-312000-12-31
> Total Assets 
420,470
595,390
680,401
1,313,879
1,250,699
1,356,479
1,551,108
1,660,224
1,777,238
1,792,759
1,860,882
2,094,535
2,201,021
2,352,182
2,434,349
2,389,275
2,754,417
3,107,188
3,023,591
3,075,601
3,259,813
3,494,611
3,253,862
3,109,937
3,094,334
3,409,279
3,429,896
3,436,283
3,448,125
3,502,380
3,586,303
3,980,178
4,025,331
4,039,287
4,109,951
4,196,158
5,452,699
5,213,434
5,551,673
5,819,258
6,634,167
6,663,879
6,609,098
7,088,663
7,485,908
8,013,725
8,976,146
10,075,831
10,212,206
11,299,384
11,561,407
12,042,643
12,921,349
14,020,681
14,436,382
14,952,634
15,412,691
15,368,617
15,718,827
15,875,867
17,126,272
17,967,337
19,074,416
20,603,545
21,531,827
22,767,454
23,227,669
24,299,297
25,171,842
24,583,765
24,911,134
24,410,486
24,012,377
24,383,422
23,193,704
16,554,956
16,493,694
16,434,984
15,775,220
16,147,338
16,541,558
16,379,684
15,666,544
16,299,588
16,430,266
17,767,652
17,195,901
17,675,438
16,714,285
17,517,010
17,604,264
17,604,26417,517,01016,714,28517,675,43817,195,90117,767,65216,430,26616,299,58815,666,54416,379,68416,541,55816,147,33815,775,22016,434,98416,493,69416,554,95623,193,70424,383,42224,012,37724,410,48624,911,13424,583,76525,171,84224,299,29723,227,66922,767,45421,531,82720,603,54519,074,41617,967,33717,126,27215,875,86715,718,82715,368,61715,412,69114,952,63414,436,38214,020,68112,921,34912,042,64311,561,40711,299,38410,212,20610,075,8318,976,1468,013,7257,485,9087,088,6636,609,0986,663,8796,634,1675,819,2585,551,6735,213,4345,452,6994,196,1584,109,9514,039,2874,025,3313,980,1783,586,3033,502,3803,448,1253,436,2833,429,8963,409,2793,094,3343,109,9373,253,8623,494,6113,259,8133,075,6013,023,5913,107,1882,754,4172,389,2752,434,3492,352,1822,201,0212,094,5351,860,8821,792,7591,777,2381,660,2241,551,1081,356,4791,250,6991,313,879680,401595,390420,470
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,646,376
17,180,817
17,818,700
17,183,663
17,530,561
17,028,434
16,541,728
17,178,341
15,999,537
9,627,493
9,237,489
8,854,185
8,124,946
8,239,290
9,249,306
9,272,047
8,572,457
8,905,412
9,228,462
9,699,035
9,027,089
9,445,430
8,732,681
9,573,840
9,758,274
9,758,2749,573,8408,732,6819,445,4309,027,0899,699,0359,228,4628,905,4128,572,4579,272,0479,249,3068,239,2908,124,9468,854,1859,237,4899,627,49315,999,53717,178,34116,541,72817,028,43417,530,56117,183,66317,818,70017,180,81716,646,376000000000000000000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,015,368
2,981,472
3,137,107
2,224,430
2,503,374
1,935,818
1,890,011
2,189,639
1,795,003
1,211,340
1,975,893
1,994,036
1,985,209
2,061,228
2,303,892
2,412,725
2,133,018
1,811,731
3,109,847
3,264,199
3,752,047
4,319,499
4,450,601
4,360,258
4,459,568
4,459,5684,360,2584,450,6014,319,4993,752,0473,264,1993,109,8471,811,7312,133,0182,412,7252,303,8922,061,2281,985,2091,994,0361,975,8931,211,3401,795,0032,189,6391,890,0111,935,8182,503,3742,224,4303,137,1072,981,4722,015,368000000000000000000000000000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
502,068
0
158,295
21,494
216,854
286,694
59,387
275,787
84,630
793,590
142,919
19,041
5,616
250,618
1,487,462
1,076,566
882,026
1,598,651
1,124,963
1,193,743
305,855
63,127
300,708
498,606
1,336,173
1,336,173498,606300,70863,127305,8551,193,7431,124,9631,598,651882,0261,076,5661,487,462250,6185,61619,041142,919793,59084,630275,78759,387286,694216,85421,494158,2950502,068000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
107,095
128,935
125,962
137,679
109,702
224,965
248,706
304,797
314,144
366,679
340,734
362,699
399,024
374,453
496,698
543,232
429,238
596,933
505,709
522,062
616,814
767,394
706,514
645,072
679,382
858,962
750,210
782,148
705,312
794,353
722,279
775,347
808,029
899,236
979,387
945,057
902,265
1,294,747
1,390,073
1,580,573
1,593,858
1,878,572
1,868,569
2,221,437
2,177,657
2,636,720
2,852,012
3,283,713
3,245,020
3,994,312
4,142,475
4,486,079
4,918,804
5,873,550
6,156,319
6,502,485
6,489,226
6,843,625
6,548,704
6,805,342
7,147,695
8,333,817
9,416,879
9,471,458
10,302,767
10,940,758
11,063,488
10,937,819
11,536,535
9,139,969
9,009,190
9,161,328
11,346,543
11,562,620
11,200,197
5,982,510
5,619,021
5,193,394
4,365,650
4,144,400
3,805,077
3,985,378
3,765,895
3,645,949
3,351,126
3,463,981
3,175,814
979,713
688,003
836,129
868,391
868,391836,129688,003979,7133,175,8143,463,9813,351,1263,645,9493,765,8953,985,3783,805,0774,144,4004,365,6505,193,3945,619,0215,982,51011,200,19711,562,62011,346,5439,161,3289,009,1909,139,96911,536,53510,937,81911,063,48810,940,75810,302,7679,471,4589,416,8798,333,8177,147,6956,805,3426,548,7046,843,6256,489,2266,502,4856,156,3195,873,5504,918,8044,486,0794,142,4753,994,3123,245,0203,283,7132,852,0122,636,7202,177,6572,221,4371,868,5691,878,5721,593,8581,580,5731,390,0731,294,747902,265945,057979,387899,236808,029775,347722,279794,353705,312782,148750,210858,962679,382645,072706,514767,394616,814522,062505,709596,933429,238543,232496,698374,453399,024362,699340,734366,679314,144304,797248,706224,965109,702137,679125,962128,935107,095
       Other Current Assets 
8,927
62,521
62,285
58,145
45,157
57,458
140,963
127,049
123,514
134,880
126,301
133,691
213,881
184,069
201,792
198,681
147,105
161,720
161,195
201,061
209,306
82,743
74,871
74,925
79,757
67,860
58,067
60,765
88,932
86,032
77,337
101,274
89,310
102,496
108,051
110,012
104,750
112,916
112,799
155,562
118,982
167,981
252,217
249,484
258,318
193,098
291,793
331,963
299,854
330,996
358,533
335,135
230,344
334,801
246,854
688,661
293,343
517,167
375,329
601,345
418,649
944,168
360,818
1,263,669
463,421
1,093,970
563,924
821,205
590,028
199,141
133,386
174,500
704,079
671,095
490,061
227,759
145,916
212,496
256,213
256,292
104,998
145,534
115,807
148,656
48,956
127,060
114,497
6,870
25,854
23,802
19,250
19,25023,80225,8546,870114,497127,06048,956148,656115,807145,534104,998256,292256,213212,496145,916227,759490,061671,095704,079174,500133,386199,141590,028821,205563,9241,093,970463,4211,263,669360,818944,168418,649601,345375,329517,167293,343688,661246,854334,801230,344335,135358,533330,996299,854331,963291,793193,098258,318249,484252,217167,981118,982155,562112,799112,916104,750110,012108,051102,49689,310101,27477,33786,03288,93260,76558,06767,86079,75774,92574,87182,743209,306201,061161,195161,720147,105198,681201,792184,069213,881133,691126,301134,880123,514127,049140,96357,45845,15758,14562,28562,5218,927
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,400,103
7,380,573
7,382,052
7,470,649
7,205,081
7,194,167
6,927,463
7,256,205
7,580,799
7,650,274
7,908,048
7,292,253
7,107,637
7,094,087
7,394,176
7,201,803
8,068,616
8,168,812
8,230,009
7,981,604
7,943,170
7,845,990
7,845,9907,943,1707,981,6048,230,0098,168,8128,068,6167,201,8037,394,1767,094,0877,107,6377,292,2537,908,0487,650,2747,580,7997,256,2056,927,4637,194,1677,205,0817,470,6497,382,0527,380,5737,400,103000000000000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
149,457
229,368
252,472
271,803
303,580
315,176
391,745
457,942
584,222
614,957
689,102
728,199
863,682
885,820
950,412
1,001,167
1,182,128
1,226,265
1,260,346
1,281,988
1,304,720
1,200,302
1,314,224
1,258,649
1,396,763
1,264,599
1,481,890
1,344,156
1,487,229
1,328,563
1,473,898
1,331,710
1,514,772
1,367,545
1,507,869
1,385,367
1,559,397
1,453,608
1,674,222
1,559,525
1,943,017
1,777,791
2,004,195
1,901,145
2,179,616
2,027,857
2,864,152
2,744,112
3,193,505
3,092,078
3,353,028
3,409,702
3,516,300
3,516,726
3,607,943
3,645,631
3,687,775
3,712,336
3,789,166
3,804,346
3,908,048
3,895,871
3,924,807
3,940,175
3,960,888
3,917,407
3,831,904
3,897,340
3,918,581
3,959,666
3,958,085
3,946,108
4,010,354
3,976,159
3,940,333
3,827,070
3,880,691
3,965,337
3,991,924
3,940,799
4,087,885
4,004,247
3,971,195
3,954,513
3,872,353
3,864,923
3,814,576
3,814,540
3,769,191
3,736,522
3,672,196
3,672,1963,736,5223,769,1913,814,5403,814,5763,864,9233,872,3533,954,5133,971,1954,004,2474,087,8853,940,7993,991,9243,965,3373,880,6913,827,0703,940,3333,976,1594,010,3543,946,1083,958,0853,959,6663,918,5813,897,3403,831,9043,917,4073,960,8883,940,1753,924,8073,895,8713,908,0483,804,3463,789,1663,712,3363,687,7753,645,6313,607,9433,516,7263,516,3003,409,7023,353,0283,092,0783,193,5052,744,1122,864,1522,027,8572,179,6161,901,1452,004,1951,777,7911,943,0171,559,5251,674,2221,453,6081,559,3971,385,3671,507,8691,367,5451,514,7721,331,7101,473,8981,328,5631,487,2291,344,1561,481,8901,264,5991,396,7631,258,6491,314,2241,200,3021,304,7201,281,9881,260,3461,226,2651,182,1281,001,167950,412885,820863,682728,199689,102614,957584,222457,942391,745315,176303,580271,803252,472229,368149,457
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
154,367
154,367
154,367
139,003
139,003
139,003
139,003
132,851
132,851
138,544
138,544
138,062
138,062
161,971
161,971
138,062
181,444
181,444
185,192
176,268
176,268
176,268
176,268
143,240
143,240
143,240
74,895
15,880
166,685
166,685
166,685
167,081
167,081
167,081
167,081
15,880
15,880
15,880
15,880
15,880
15,880
15,880
15,88015,88015,88015,88015,88015,88015,880167,081167,081167,081167,081166,685166,685166,68515,88074,895143,240143,240143,240176,268176,268176,268176,268185,192181,444181,444138,062161,971161,971138,062138,062138,544138,544132,851132,851139,003139,003139,003139,003154,367154,367154,3670000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,254,201
1,336,594
1,362,133
1,368,975
1,279,902
1,183,685
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,183,6851,279,9021,368,9751,362,1331,336,5941,254,201000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
16,074
13,549
12,286
11,686
49,978
48,114
65,732
81,403
43,935
41,502
39,083
104,655
100,275
96,217
87,449
89,355
83,709
85,533
77,122
79,827
77,285
348,978
69,880
346,016
64,201
359,171
58,467
368,344
52,898
375,769
46,974
384,828
25,170
314,033
22,718
319,767
27,393
319,309
65,821
368,998
99,059
413,723
89,747
423,350
49,313
418,683
88,895
727,327
86,085
518,654
550,478
543,961
549,371
548,774
537,100
555,058
621,594
618,195
659,486
652,942
653,657
649,168
724,597
717,374
633,318
625,479
418,528
440,359
409,778
1,589,021
1,314,478
1,744,247
1,809,171
1,815,324
1,804,687
1,757,868
1,646,411
1,671,985
1,720,594
1,808,246
1,625,535
1,631,282
1,658,217
1,721,034
1,584,458
1,735,031
1,945,968
2,007,102
2,026,535
2,052,257
2,100,913
2,100,9132,052,2572,026,5352,007,1021,945,9681,735,0311,584,4581,721,0341,658,2171,631,2821,625,5351,808,2461,720,5941,671,9851,646,4111,757,8681,804,6871,815,3241,809,1711,744,2471,314,4781,589,021409,778440,359418,528625,479633,318717,374724,597649,168653,657652,942659,486618,195621,594555,058537,100548,774549,371543,961550,478518,65486,085727,32788,895418,68349,313423,35089,747413,72399,059368,99865,821319,30927,393319,76722,718314,03325,170384,82846,974375,76952,898368,34458,467359,17164,201346,01669,880348,97877,28579,82777,12285,53383,70989,35587,44996,217100,275104,65539,08341,50243,93581,40365,73248,11449,97811,68612,28613,54916,074
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
254,689
257,719
257,719
449
449
3,032
3,830,103
8,447
74,021
69,967
2,987
79,682
91,340
68,709
71,572
101,904
98,600
41,943
50,000
43,142
37,353
49,902
49,90237,35343,14250,00041,94398,600101,90471,57268,70991,34079,6822,98769,96774,0218,4473,830,1033,032449449257,719257,719254,689000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
264,148
348,193
381,032
259,384
253,698
311,257
451,445
534,094
575,744
568,607
682,761
793,509
826,416
926,856
990,763
899,440
1,189,505
1,585,205
1,447,499
1,449,358
1,539,769
1,478,169
1,275,314
1,102,710
1,119,610
1,396,722
1,496,927
1,443,215
1,355,221
1,568,511
1,567,147
1,873,201
1,854,233
1,809,828
1,975,919
1,930,650
2,027,759
1,631,295
2,071,775
2,157,051
2,858,148
2,743,890
2,793,286
3,045,921
3,279,367
3,588,350
5,404,437
6,156,649
6,068,714
6,891,178
7,124,295
7,195,774
7,852,890
7,020,007
7,370,386
7,503,360
7,705,760
7,376,407
7,820,250
7,648,579
8,919,577
9,437,876
10,641,173
11,783,983
12,557,337
13,327,058
13,638,951
13,307,489
13,963,583
12,896,870
13,241,962
12,545,684
12,150,004
12,245,507
11,074,320
4,425,134
4,109,459
3,779,143
2,978,506
2,801,165
3,227,837
3,690,685
3,335,802
3,802,307
3,760,496
4,947,312
4,669,663
4,953,885
4,024,276
4,539,561
4,761,275
4,761,2754,539,5614,024,2764,953,8854,669,6634,947,3123,760,4963,802,3073,335,8023,690,6853,227,8372,801,1652,978,5063,779,1434,109,4594,425,13411,074,32012,245,50712,150,00412,545,68413,241,96212,896,87013,963,58313,307,48913,638,95113,327,05812,557,33711,783,98310,641,1739,437,8768,919,5777,648,5797,820,2507,376,4077,705,7607,503,3607,370,3867,020,0077,852,8907,195,7747,124,2956,891,1786,068,7146,156,6495,404,4373,588,3503,279,3673,045,9212,793,2862,743,8902,858,1482,157,0512,071,7751,631,2952,027,7591,930,6501,975,9191,809,8281,854,2331,873,2011,567,1471,568,5111,355,2211,443,2151,496,9271,396,7221,119,6101,102,7101,275,3141,478,1691,539,7691,449,3581,447,4991,585,2051,189,505899,440990,763926,856826,416793,509682,761568,607575,744534,094451,445311,257253,698259,384381,032348,193264,148
   > Total Current Liabilities 
214,148
298,193
295,032
223,384
198,718
256,223
394,465
477,115
516,114
509,477
660,800
771,690
801,270
901,996
884,133
772,419
936,977
1,334,553
1,151,427
1,153,635
1,291,999
1,229,174
1,032,819
781,705
905,611
1,228,461
1,328,162
1,273,972
1,236,281
1,450,467
1,323,538
1,543,295
1,611,214
1,563,521
1,725,089
1,680,242
1,780,153
1,382,059
1,820,770
1,882,536
2,738,528
2,618,026
2,238,280
2,485,953
2,702,868
2,998,262
4,304,889
5,010,934
4,989,704
5,805,122
5,988,621
6,052,576
6,766,840
5,936,972
6,296,938
6,413,760
6,586,122
6,244,832
7,066,462
6,882,126
8,158,639
8,632,318
10,240,139
11,307,735
11,339,887
10,356,066
9,337,251
9,188,740
8,515,590
7,779,959
8,590,277
7,886,655
8,657,109
8,651,354
8,701,300
3,348,974
2,831,866
2,745,932
1,362,071
1,330,645
1,855,054
2,524,321
2,266,659
2,194,154
2,108,596
2,808,041
2,610,002
2,990,452
2,369,556
2,852,780
3,303,741
3,303,7412,852,7802,369,5562,990,4522,610,0022,808,0412,108,5962,194,1542,266,6592,524,3211,855,0541,330,6451,362,0712,745,9322,831,8663,348,9748,701,3008,651,3548,657,1097,886,6558,590,2777,779,9598,515,5909,188,7409,337,25110,356,06611,339,88711,307,73510,240,1398,632,3188,158,6396,882,1267,066,4626,244,8326,586,1226,413,7606,296,9385,936,9726,766,8406,052,5765,988,6215,805,1224,989,7045,010,9344,304,8892,998,2622,702,8682,485,9532,238,2802,618,0262,738,5281,882,5361,820,7701,382,0591,780,1531,680,2421,725,0891,563,5211,611,2141,543,2951,323,5381,450,4671,236,2811,273,9721,328,1621,228,461905,611781,7051,032,8191,229,1741,291,9991,153,6351,151,4271,334,553936,977772,419884,133901,996801,270771,690660,800509,477516,114477,115394,465256,223198,718223,384295,032298,193214,148
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
524,700
588,550
2,730,865
3,068,263
2,913,839
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002,913,8393,068,2632,730,865588,550524,7000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
524,700
588,550
2,730,865
3,068,263
2,913,839
2,650,325
3,386,485
3,170,927
894,135
637,307
146,330
173,167
177,653
177,939
476,023
327,998
472,990
184,478
934,968
941,892
1,215,055
723,051
663,367
823,420
823,420663,367723,0511,215,055941,892934,968184,478472,990327,998476,023177,939177,653173,167146,330637,307894,1353,170,9273,386,4852,650,3252,913,8393,068,2632,730,865588,550524,7000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
16,161
28,775
23,545
41,522
40,759
97,066
153,533
166,921
87,206
165,863
144,075
161,207
163,585
195,684
222,545
264,415
361,331
699,479
524,927
358,668
348,162
434,930
383,544
333,580
350,167
393,596
375,092
410,892
495,134
544,486
563,591
771,451
640,194
735,242
645,203
683,977
745,064
709,670
736,398
840,236
902,572
1,163,819
1,066,577
1,184,685
1,287,539
1,450,979
1,436,933
1,470,364
1,490,664
1,923,117
1,805,593
1,993,693
2,501,054
2,449,857
2,316,134
2,578,885
2,375,134
2,627,963
2,421,701
2,354,024
2,721,002
2,872,189
2,572,389
2,740,793
2,681,494
3,212,818
3,088,944
3,443,077
2,828,030
2,944,919
2,886,682
2,982,074
2,746,871
2,538,122
2,426,099
523,862
572,517
719,152
570,384
646,578
603,785
1,170,637
759,740
901,659
868,880
843,389
674,317
809,873
572,726
1,246,899
1,590,932
1,590,9321,246,899572,726809,873674,317843,389868,880901,659759,7401,170,637603,785646,578570,384719,152572,517523,8622,426,0992,538,1222,746,8712,982,0742,886,6822,944,9192,828,0303,443,0773,088,9443,212,8182,681,4942,740,7932,572,3892,872,1892,721,0022,354,0242,421,7012,627,9632,375,1342,578,8852,316,1342,449,8572,501,0541,993,6931,805,5931,923,1171,490,6641,470,3641,436,9331,450,9791,287,5391,184,6851,066,5771,163,819902,572840,236736,398709,670745,064683,977645,203735,242640,194771,451563,591544,486495,134410,892375,092393,596350,167333,580383,544434,930348,162358,668524,927699,479361,331264,415222,545195,684163,585161,207144,075165,86387,206166,921153,53397,06640,75941,52223,54528,77516,161
       Other Current Liabilities 
115,287
54,418
64,987
55,902
154,459
152,657
67,932
141,994
105,908
90,594
210,725
134,483
147,953
105,312
116,588
111,004
120,646
193,074
119,500
127,467
628,871
590,778
597,375
106,725
168,652
148,965
181,170
166,180
120,586
318,977
153,047
150,122
167,072
161,464
233,319
173,598
230,833
209,331
216,471
218,218
663,227
693,258
930,996
967,389
1,087,694
1,104,386
1,927,242
2,052,751
1,638,612
677,386
615,483
481,411
762,133
584,936
622,384
975,321
726,733
498,609
566,024
467,260
951,853
578,357
783,255
652,515
1,261,974
1,034,225
946,372
646,938
919,428
1,053,550
1,652,009
99,940
754,420
1,049,808
726,886
339,449
283,279
295,261
354,838
307,326
450,336
448,161
398,660
330,374
413,371
469,177
371,081
68,059
79,665
70,455
70,043
70,04370,45579,66568,059371,081469,177413,371330,374398,660448,161450,336307,326354,838295,261283,279339,449726,8861,049,808754,42099,9401,652,0091,053,550919,428646,938946,3721,034,2251,261,974652,515783,255578,357951,853467,260566,024498,609726,733975,321622,384584,936762,133481,411615,483677,3861,638,6122,052,7511,927,2421,104,3861,087,694967,389930,996693,258663,227218,218216,471209,331230,833173,598233,319161,464167,072150,122153,047318,977120,586166,180181,170148,965168,652106,725597,375590,778628,871127,467119,500193,074120,646111,004116,588105,312147,953134,483210,72590,594105,908141,99467,932152,657154,45955,90264,98754,418115,287
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,116,911
4,651,685
4,659,029
3,492,895
3,594,154
2,373,019
1,076,160
1,277,593
1,033,211
1,616,435
1,470,520
1,372,783
1,166,364
1,069,142
1,608,153
1,651,901
2,139,271
2,059,660
1,963,433
1,654,720
1,686,781
1,457,534
1,457,5341,686,7811,654,7201,963,4332,059,6602,139,2711,651,9011,608,1531,069,1421,166,3641,372,7831,470,5201,616,4351,033,2111,277,5931,076,1602,373,0193,594,1543,492,8954,659,0294,651,6855,116,911000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
18,980
19,034
20,980
20,979
23,630
23,130
21,961
21,819
25,146
24,860
26,630
27,021
28,528
26,652
27,072
26,723
20,770
21,995
25,495
24,005
18,999
18,261
18,765
19,243
18,940
18,044
18,609
24,906
18,019
21,307
25,830
25,408
22,606
24,236
26,005
49,515
56,611
62,921
74,693
73,318
75,798
79,263
191,033
215,816
210,362
215,061
264,700
271,997
271,933
268,720
273,802
289,727
319,537
331,250
352,831
365,633
360,016
354,246
349,852
350,912
324,765
314,063
336,374
285,834
291,196
296,480
283,861
279,662
260,160
257,141
256,277
249,160
257,102
252,001
256,302
282,968
256,749
237,113
229,906
217,357
200,627
197,089
183,822
0
0
0
0
0000183,822197,089200,627217,357229,906237,113256,749282,968256,302252,001257,102249,160256,277257,141260,160279,662283,861296,480291,196285,834336,374314,063324,765350,912349,852354,246360,016365,633352,831331,250319,537289,727273,802268,720271,933271,997264,700215,061210,362215,816191,03379,26375,79873,31874,69362,92156,61149,51526,00524,23622,60625,40825,83021,30718,01924,90618,60918,04418,94019,24318,76518,26118,99924,00525,49521,99520,77026,72327,07226,65228,52827,02126,63024,86025,14621,81921,96123,13023,63020,97920,98019,03418,9800000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
781,750
1,129,237
1,338,788
1,351,039
1,389,526
1,512,696
1,579,442
1,600,074
1,612,541
1,603,574
1,411,753
1,389,035
1,408,207
1,458,443
1,193,268
1,211,259
1,234,540
1,295,201
1,156,695
1,201,060
1,250,457
0
0
0
0
00001,250,4571,201,0601,156,6951,295,2011,234,5401,211,2591,193,2681,458,4431,408,2071,389,0351,411,7531,603,5741,612,5411,600,0741,579,4421,512,6961,389,5261,351,0391,338,7881,129,237781,750000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
150,053
238,796
286,390
1,025,258
972,902
992,514
1,025,936
1,052,820
1,114,115
1,136,350
1,089,214
1,131,165
1,200,259
1,225,722
1,184,373
1,230,270
1,308,315
1,249,849
1,300,348
1,349,544
1,434,675
1,740,312
1,701,549
1,742,967
1,818,288
1,859,527
1,760,278
1,815,990
1,911,868
1,768,924
1,854,349
1,941,945
2,033,369
2,100,426
2,021,805
2,149,530
3,306,590
3,466,629
3,353,384
3,516,096
3,603,950
3,751,321
3,646,220
3,867,880
4,011,648
4,232,075
3,351,433
3,657,660
3,832,157
4,114,184
4,214,976
4,610,705
4,837,880
6,760,790
6,823,687
7,212,605
7,469,484
7,746,563
7,666,792
7,985,049
7,963,843
8,282,105
8,118,502
8,501,270
8,654,533
9,026,858
9,169,170
10,378,683
10,533,702
11,004,446
10,978,425
11,120,540
11,130,326
11,428,196
11,392,037
11,703,335
11,972,467
12,286,084
12,402,980
12,920,066
12,981,164
12,394,517
12,033,868
12,213,645
12,404,916
12,559,246
12,182,443
12,402,412
12,368,420
12,658,473
12,531,089
12,531,08912,658,47312,368,42012,402,41212,182,44312,559,24612,404,91612,213,64512,033,86812,394,51712,981,16412,920,06612,402,98012,286,08411,972,46711,703,33511,392,03711,428,19611,130,32611,120,54010,978,42511,004,44610,533,70210,378,6839,169,1709,026,8588,654,5338,501,2708,118,5028,282,1057,963,8437,985,0497,666,7927,746,5637,469,4847,212,6056,823,6876,760,7904,837,8804,610,7054,214,9764,114,1843,832,1573,657,6603,351,4334,232,0754,011,6483,867,8803,646,2203,751,3213,603,9503,516,0963,353,3843,466,6293,306,5902,149,5302,021,8052,100,4262,033,3691,941,9451,854,3491,768,9241,911,8681,815,9901,760,2781,859,5271,818,2881,742,9671,701,5491,740,3121,434,6751,349,5441,300,3481,249,8491,308,3151,230,2701,184,3731,225,7221,200,2591,131,1651,089,2141,136,3501,114,1151,052,8201,025,936992,514972,9021,025,258286,390238,796150,053
   Common Stock
140,000
140,000
140,000
190,000
190,000
190,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
285,000
305,000
488,000
488,000
488,000
488,000
488,000
488,000
488,000
488,000
488,000
488,000
488,000
488,000
488,000
488,000
516,421
516,421
516,421
516,421
516,421
516,421
516,421
516,421
516,421
516,421
1,032,843
1,032,843
1,032,843
1,032,843
1,032,843
1,032,843
1,032,843
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,080,476
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,512,666
1,507,920
1,499,700
1,499,700
1,499,700
1,499,700
1,499,700
0
0
0
0
00001,499,7001,499,7001,499,7001,499,7001,499,7001,507,9201,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,512,6661,080,4761,080,4761,080,4761,080,4761,080,4761,080,4761,080,4761,080,4761,080,4761,080,4761,080,4761,080,4761,080,4761,032,8431,032,8431,032,8431,032,8431,032,8431,032,8431,032,843516,421516,421516,421516,421516,421516,421516,421516,421516,421516,421488,000488,000488,000488,000488,000488,000488,000488,000488,000488,000488,000488,000488,000488,000305,000285,000285,000285,000285,000285,000285,000285,000285,000285,000285,000285,000285,000285,000285,000285,000190,000190,000190,000140,000140,000140,000
   Retained Earnings 
100
73,640
121,234
148,845
78,978
98,590
132,012
158,896
198,410
220,645
173,143
215,094
259,597
285,060
243,711
289,608
338,581
280,116
330,614
379,810
437,073
461,012
422,382
466,687
532,080
573,680
482,092
541,548
671,987
529,142
614,597
702,182
760,419
827,479
760,753
888,565
971,390
1,131,523
1,021,866
1,184,796
1,213,642
1,361,302
1,256,012
1,477,619
1,548,413
1,768,928
1,671,459
1,974,027
2,047,751
2,852,678
2,938,400
3,334,092
3,562,174
3,907,692
3,970,868
4,359,438
4,619,338
4,896,381
4,850,323
5,168,646
5,341,963
5,660,113
5,493,124
5,875,432
6,113,439
6,484,953
6,610,458
7,050,266
7,226,416
6,603,276
6,601,216
6,834,753
7,730,321
8,025,187
7,918,674
8,332,627
8,358,599
8,681,563
8,865,055
9,343,894
10,221,748
9,664,561
9,320,986
9,394,264
9,472,231
9,738,309
9,595,867
8,396,153
8,291,751
8,586,962
8,461,056
8,461,0568,586,9628,291,7518,396,1539,595,8679,738,3099,472,2319,394,2649,320,9869,664,56110,221,7489,343,8948,865,0558,681,5638,358,5998,332,6277,918,6748,025,1877,730,3216,834,7536,601,2166,603,2767,226,4167,050,2666,610,4586,484,9536,113,4395,875,4325,493,1245,660,1135,341,9635,168,6464,850,3234,896,3814,619,3384,359,4383,970,8683,907,6923,562,1743,334,0922,938,4002,852,6782,047,7511,974,0271,671,4591,768,9281,548,4131,477,6191,256,0121,361,3021,213,6421,184,7961,021,8661,131,523971,390888,565760,753827,479760,419702,182614,597529,142671,987541,548482,092573,680532,080466,687422,382461,012437,073379,810330,614280,116338,581289,608243,711285,060259,597215,094173,143220,645198,410158,896132,01298,59078,978148,845121,23473,640100
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000-68,1380000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-14,400
-12,861
-47,959
-12,528
-36,489
-127,911
-1,893
522
319
-9,115
-25,098
-23,227
-27,634
-31,077
-32,190
-33,100
-18,990
87,508
211,863
97,144
136,731
0
0
0
0
0000136,73197,144211,86387,508-18,990-33,100-32,190-31,077-27,634-23,227-25,098-9,115319522-1,893-127,911-36,489-12,528-47,959-12,861-14,400000000000000000000000000000000000000000000000000000000000000000000



6.3. Balance Sheets

Currency in CNY. All numbers in thousands.




6.4. Cash Flows

Currency in CNY. All numbers in thousands.




6.5. Income Statements

Currency in CNY. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in CNY. All numbers in thousands.

Gross Profit (+$)
totalRevenue8,674,014
Cost of Revenue-2,880,103
Gross Profit5,793,9115,793,911
 
Operating Income (+$)
Gross Profit5,793,911
Operating Expense-7,169,209
Operating Income1,504,805-1,375,297
 
Operating Expense (+$)
Research Development917,269
Selling General Administrative3,066,273
Selling And Marketing Expenses0
Operating Expense7,169,2093,983,542
 
Net Interest Income (+$)
Interest Income107,545
Interest Expense-82,524
Other Finance Cost-4,734
Net Interest Income20,287
 
Pretax Income (+$)
Operating Income1,504,805
Net Interest Income20,287
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,221,0971,504,805
EBIT - interestExpense = -82,524
1,071,072
1,153,597
Interest Expense82,524
Earnings Before Interest and Taxes (EBIT)01,303,621
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax1,221,097
Tax Provision-204,457
Net Income From Continuing Ops1,016,6401,016,640
Net Income1,071,072
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-20,287
 

Technical Analysis of Tasly Pharmaceutical Group Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Tasly Pharmaceutical Group Co Ltd. The general trend of Tasly Pharmaceutical Group Co Ltd is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Tasly Pharmaceutical Group Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Tasly Pharmaceutical Group Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 15.64 < 17.48 < 17.65.

The bearish price targets are: 14.79 > 14.64 > 14.64.

Tweet this
Tasly Pharmaceutical Group Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Tasly Pharmaceutical Group Co Ltd. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Tasly Pharmaceutical Group Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Tasly Pharmaceutical Group Co Ltd. The current macd is 0.13607964.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Tasly Pharmaceutical Group Co Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Tasly Pharmaceutical Group Co Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Tasly Pharmaceutical Group Co Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Tasly Pharmaceutical Group Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartTasly Pharmaceutical Group Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Tasly Pharmaceutical Group Co Ltd. The current adx is 23.15.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Tasly Pharmaceutical Group Co Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Tasly Pharmaceutical Group Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Tasly Pharmaceutical Group Co Ltd. The current sar is 16.70.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Tasly Pharmaceutical Group Co Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Tasly Pharmaceutical Group Co Ltd. The current rsi is 49.57. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Tasly Pharmaceutical Group Co Ltd Daily Relative Strength Index (RSI) ChartTasly Pharmaceutical Group Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Tasly Pharmaceutical Group Co Ltd. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Tasly Pharmaceutical Group Co Ltd price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Tasly Pharmaceutical Group Co Ltd Daily Stochastic Oscillator ChartTasly Pharmaceutical Group Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Tasly Pharmaceutical Group Co Ltd. The current cci is -82.32048034.

Tasly Pharmaceutical Group Co Ltd Daily Commodity Channel Index (CCI) ChartTasly Pharmaceutical Group Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Tasly Pharmaceutical Group Co Ltd. The current cmo is -8.47389406.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Tasly Pharmaceutical Group Co Ltd Daily Chande Momentum Oscillator (CMO) ChartTasly Pharmaceutical Group Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Tasly Pharmaceutical Group Co Ltd. The current willr is -65.48672566.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Tasly Pharmaceutical Group Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Tasly Pharmaceutical Group Co Ltd Daily Williams %R ChartTasly Pharmaceutical Group Co Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Tasly Pharmaceutical Group Co Ltd.

Tasly Pharmaceutical Group Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Tasly Pharmaceutical Group Co Ltd. The current atr is 0.49530518.

Tasly Pharmaceutical Group Co Ltd Daily Average True Range (ATR) ChartTasly Pharmaceutical Group Co Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Tasly Pharmaceutical Group Co Ltd. The current obv is 736,693,659.

Tasly Pharmaceutical Group Co Ltd Daily On-Balance Volume (OBV) ChartTasly Pharmaceutical Group Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Tasly Pharmaceutical Group Co Ltd. The current mfi is 47.17.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Tasly Pharmaceutical Group Co Ltd Daily Money Flow Index (MFI) ChartTasly Pharmaceutical Group Co Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Tasly Pharmaceutical Group Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-22STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-31BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-30ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-30STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Tasly Pharmaceutical Group Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Tasly Pharmaceutical Group Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.571
Ma 20Greater thanMa 5015.298
Ma 50Greater thanMa 10014.526
Ma 100Greater thanMa 20013.898
OpenGreater thanClose14.890
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Tasly Pharmaceutical Group Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Tasly Pharmaceutical Group Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Tasly Pharmaceutical Group Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Tasly Pharmaceutical Group Co Ltd

I send you an email if I find something interesting about Tasly Pharmaceutical Group Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Tasly Pharmaceutical Group Co Ltd.

Receive notifications about Tasly Pharmaceutical Group Co Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.